Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. orthocat

ORTHOCAT SIGNED

Bioorthogonal Photocatalytic Activation of Metal-Based Prodrugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ORTHOCAT project word cloud

Explore the words cloud of the ORTHOCAT project. It provides you a very rough idea of what is the project "ORTHOCAT" about.

redox    innovative    homeostasis    mitochondrial    complexes    convenient    catalytic    riboflavin    compounds    simultaneously    depends    outcome    photocatalytic    inside    pt    reducing    cellular    selectivity    pdt    prodrug    selectively    photoactivatable    cell    new    4619    designing    action    agents    mechanism    activating    oxygen    successful    cells    generate    patient    kill    drugs    chem    intimately    framework    employing    nevertheless    strategy    class    2017    species    photodynamic    mitochondria    orthocat    organelle    effectiveness    photocatalyst    photochemistry    original    efficiency    clinics    hypoxic    imbalance    light    tumour    metal    sci    triphenylphosphonium    care    transition    synergistically    once    dual    accumulate    strategies    limits    death    solid    singlet    wellbeing    background    combines    photochemotherapy    fewer    involve    therapy    surgery    activation    proposes    potentially    photosensitizer    dna    mission    vectors    delicate    act    unconventional    therapeutic    nanoplatforms    trigger    accomplishes    prodrugs    tumours    multidisciplinary    cancer    vast    efficacy    anticancer   

Project "ORTHOCAT" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER 

Organization address
address: PASEO MANUEL LARDIZABAL 4
city: DONOSTIA SAN SEBASTIAN
postcode: 20018
website: http://dipc.ehu.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-10   to  2020-09-09

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER ES (DONOSTIA SAN SEBASTIAN) coordinator 158˙121.00

Map

 Project objective

New cancer care methodologies with fewer side effects and no need for major surgery are required to enhance patient wellbeing. Photodynamic Therapy (PDT) partially accomplishes such mission employing light and a photosensitizer. Nevertheless, the PDT mechanism of action intimately depends on oxygen, which limits its efficacy, particularly in hypoxic solid tumours. Promising strategies to improve the impact of PDT in the clinics currently involve the design of photoactivatable transition metal complexes, a class of compounds which combines the rich photochemistry of metal complexes with the vast background of metal-based drugs in cancer therapy.

In this framework, ORTHOCAT proposes an original and multidisciplinary strategy to exploit the efficiency and selectivity of riboflavin as unconventional photocatalyst for the activation of Pt(IV) anticancer prodrugs (Chem. Sci. 2017, 8, 4619).

The project aims at designing novel riboflavin-based catalytic systems capable of activating Pt(IV) anticancer prodrugs inside the mitochondria of tumour cells. In particular, I will use triphenylphosphonium targeting vectors to develop new photocatalytic prodrug systems and delivery nanoplatforms which selectively accumulate in the mitochondria. Once in the organelle, riboflavin will act as singlet oxygen photosensitizer for PDT and simultaneously as photocatalyst to generate Pt(II) species for targeting mitochondrial DNA (photochemotherapy). Imbalance of mitochondrial delicate redox homeostasis by ORTHOCAT dual agents can trigger cell death through convenient cellular pathways. Therefore, ORTHOCAT prodrug systems will synergistically kill cancer cells with increased effectiveness, while potentially reducing side effects of metal-based drugs. Successful outcome of the project has the potential to deliver innovative therapeutic agents for cancer photochemotherapy.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-08-05 15:14:49

Take a look to the deliverables list in detail:  detailed list of ORTHOCAT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORTHOCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORTHOCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

HSQG (2020)

Higher Spin Quantum Gravity: Lagrangian Formulations for Higher Spin Gravity and Their Applications

Read More  

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More